Skip to content

Surgical and Patient Reported Outcomes in Robotic Mastectomy

Pilot Robotic Mastectomy in Singapore (PRoMiSing I) Study: First Safety and Feasibility Prospective Cohort Study in South East Asia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06335550
Enrollment
29
Registered
2024-03-28
Start date
2022-11-24
Completion date
2024-03-01
Last updated
2024-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer, Minimally invasive breast surgery, endoscopic breast surgery, robotic breast surgery

Brief summary

Conventional nipple and/or skin-sparing mastectomy (NSM/SSM) with or without immediate reconstruction is becoming one of the mainstream surgical treatment for breast cancer and risk reducing mastectomy in recent years. While this technique provides satisfactory oncologic and aesthetic outcomes, its disadvantages include skin flap and/or nipple-areolar complex (NAC) necrosis, NAC malposition/distortion as well as visible scar(s) on the breast. In terms of technical aspects, NSM/SSM has its inherent challenges in view of limited incisions and thereby difficulties in dissection. Since 2015, a number of institutions worldwide had adopted a new technique of NSM/SSM using robotic surgical system. Institutional experiences worldwide demonstrated feasibility and safety of this technique coupled with improved patients' satisfactions. To date, there is no center in Singapore or the region offering Robotic NSM/SSM (R-NSM/R-SSM). The authors believe that robotic mastectomy is a feasible and safe technique that can be utilized in our institution and it provides superior aesthetic outcomes with less morbidity and higher patient satisfaction if compared to conventional NSM/SSM. The aim of this study is to conduct a single-arm prospective pilot study to investigate the safety and feasibility as well as learning curve of R-NSM/R-SSM.

Interventions

PROCEDURERobotic mastectomy

Robotic mastectomy with or without reconstruction

Sponsors

Changi General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Women aged 21-70, with invasive breast cancer, ductal carcinoma in situ (DCIS), Breast Cancer (BRCA) gene or other breast cancer genetic mutation carriers or high risk female patients who are otherwise candidates for conventional NSM/SSM will be eligible for the study. All suitable patients will be offered the option of R-NSM/ R-SSM. For patients with breast cancer (invasive or DCIS), selection criteria include but not limited to: 1. Early breast cancer 2. Tumor size less than 5 cm 3. No evidence of lymph node metastases 4. No evidence of skin or chest wall invasion.

Exclusion criteria

1. Extensive axillary lymph node metastasis (Stage 3B or later) 2. Heavy smokers (\>20 cigarettes a day) 3. High risk patient with severe and poorly controlled co-morbid conditions (include but not limited to diabetes, heart disease, renal failure or liver dysfunction) 4. Poor performance status or high risk for anaesthesia (ASA 3 and above) 5. Inflammatory or Locally Advanced Breast Cancer (with or without chest wall or skin invasion)

Design outcomes

Primary

MeasureTime frameDescription
Surgical Outcomes - Operative parametersPostoperative Day 0-1\- Operative parameters (in terms of docking time/console time and total operative time - defined as time taken from axilla staging procedure, robot docking time, console time, closure and time taken for reconstruction, if applicable
Surgical Outcomes - Length of stay (days)Postoperative 30 days\- Length of stay (days)
Surgical Outcomes- 30-days morbidity/complicationsPostoperative 30 days\- 30-days morbidity/complications

Secondary

MeasureTime frameDescription
Oncologic outcomesPostoperative 2 weeks until final histopathology results are availableShort-term oncologic outcomes, such as positivity of margins
Learning curvePostoperative up to 2 years throughout study recruitmentLearning curve analysis using cumulative sum (CUSUM) method

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026